Get Adobe Flash player

Eleventh International Kidney Cancer Symposium Presentation Notes An Overview of the Proceedings Joyce Graff FounderWellness Director VHL Family Alliance Michael B. Lawing Patient Advocate Liaison Ki

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 2 The Eleventh International Kidney Cancer Symposium 2012 Reporting by Joyce W. Graff, VHL Family Alliance Executive Summar

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 3 significantly shrink the tumor, so surgery is probably the first course of action, but there should be a plan in place for

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 4 CommentaryLayout Michael B. Lawing, KCA Patient Advocacy Volunteer Dear Fellow Travelers As I complete my fifteenth year

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 5 A World Without Kidney Cancer The Vision of the Kidney Cancer Association The Kidney Cancer Association KCA is a charitab

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 6 smartphone educational applications for the iPad, iPhone, and Android platforms. We sponsored the Sixth European Kidney Ca

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 7 Our capacity to attain these objectives, as well as being able to identify new ones, relies primarily on the level of publ

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 8 Contents The Eleventh International Kidney Cancer Symposium 2012 .........................................................

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 9 Management of Small Renal Masses This section, moderated by Dr. Jason Abel of the University of Wisconsin, was framed as a

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 10 the natural movements of the surgeons hands, so the training time is lower. Nonetheless the technology is still relativel

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 11 Dr. Inderbir Andy Gill, University of Southern California, was tasked with taking the Con position. He began by telling u

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 12 Dr. Houston Thompson Mayo Clinic, Minnesota presented methods for saving nephrons during partial nephrectomy for small re

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 13 Dr. David Miller U Michigan spoke about partial nephrectomy. As a clinical oncologist, he works with outcome analysis how

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 14 Management of Localized and Locally Advanced RCC Dr. Christopher Weight U Minnesota Case presentation 56 year old man wit

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 15 A Biopsy can tell you about the tissue type, but not about the grade and stage. The ECOG performance status scale rates t

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 16 Consider pretreatment with anticoagulation medication to keep from encountering more problems during surgery. Dr. Leibovi

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 17 Dr. E. Jason Abel U Wisconsin, Role of Lymph Node Dissection Dr. Abel began by stating that all studies of this question

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 18 Dr. Chris Wood MD Anderson Cancer Center, Summary of Options for Locally Advanced Disease Dr. Wood summarized by presenti

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 19 A Dedication to Andrew C. Novick, M.D. Excerpts from the Dedication page of Guideline for Management of the Clinical St

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 20 Sept, 2010 Michael L. Blute, MD, invested as the Mary C. DeFeudis Chair of Cancer and Research at the University of Mass

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 21 One major predictor of poor survival no surgical history. Metastatic RCC treated with targeted therapy without cytoreduct

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 22 Where are we going presurgical targeted therapy followed by debulking surgery risk of major surgical complications i

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 23 Invited Abstracts from Young Investigators Dr. Benjamin P. Casavant U Wisconsin Isolation of RCC Cells Dr. Casavant is an

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 24 Kritti Mittal, M.D., Cleveland Clinic, Detection of Circulating Tumor Cells Dr. Mittal uses immunomagnetic enrichment to

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 25 Sumanta Pal, M.D. City of Hope Comprehensive Cancer Center, Sumanta CA Duarte, Impact of Age on Treatment Trends and Cli

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 26 Tumor Suppressor Screens of 3p Chromatic Modulators Link BAPI Mutations to Poor Clinical Outcomes in ccRCC Abraham Hakimi

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 27 Recent Insights into RCC Biology Does Hereditary and Sporadic Type 2 Papillary RCC Converge at Sustained NRF2 Activation

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 28 Charles Swanton, M.D., Univ College London The Challenges of Genetics Heterogeneity to RCC Translational Research Is ther

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 29 Pankaj Seth, Ph.D. Beth Israel, Boston, Inhibiting RCC Metabolism In addition to the VEGF pathway, VHL also performs a fu

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 30 Dr. Elisabeth Henske, Beth Israel Deaconess Dana Farber Harvard New Targets for the NonCC RCC BirtHoggDube Rare genetic s

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 31 W. Kimryn Rathmell, M.D., Ph. D., U North Carolina, Future Directions in RCC Translational Research What have we learned

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 32 Patient Management Issues Elisabeth Heath, M.D., Karmanos Cancer Institute, Wayne State Univ, Michigan Importance of Dose

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 33 There is a model of tumor growth dynamics using serial measurements of the sum of the longest tumor diameter from patient

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 34 Disparities in RCC Therapy, Dr. Ulka Vaishampayan Karmanos, Wayne State, Michigan Patients over 65 do respond, but not to

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 35 Dr. Naomi Haas U Penn Does Adjuvant Therapy Produce Toxicity Concerns There have been concerns about cardiac related adve

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 36 Special Session Results of the BeST Trial Bevacizumab, Sorafenib, Temsirolimus Keith Flaherty, M.D., Massachusetts Genera

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 37 Rational Combination Therapy for RCC, Bernard Escudier, M.D, Institut GustaveRoussy France The combination of mTOR inhibi

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 38 Surgery The Setting of Metastatic Disease Moderator Dr. Andrew Wagner, Beth Israel Deaconess, Boston Stephen Culp, M.D.

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 39 Role of Neoadjuvant Medical Treatment Dr. Eric Jonasch MDACC Today the standard of care is cytoreductive surgery targete

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 40 Having the posttreatment renal mass gives us information about how things change, so we can evaluate the results did the

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 41 Role of Metastastectomy, Stephen Boorjian, M.D. Mayo clinic What is the role of surgical resection of mets does it help H

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 42 Scott Eggener, M.D., U Chicago, Summary of surgical options for metastatic disease Cytoreductive Nephrectomy CN randomiz

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 43 QA On Surgery and The Setting of Metastatic Disease Blute We are redesigning our approach to cancer patients. Jonasch Any

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 44 Case for Moving Axitinib into the Front Line, Dr. Brian Rini, Cleveland Clinic Rini feels axitinib is now the standard of

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 45 Dr. Camillo Porta Pavia, Italy, San Matteo Univ How Does Recent Pazopanib Data Impact Our Prescription Paradigm The PISC

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 46 Tivozanib as Firstline Therapy for mRCC, Dr. Robert J. Motzer, MSKCC Dr. Motzer said that Tivozanib is showing efficacy,

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 47 Dr. Tim Eisen, Univ of Cambridge, England Does Emerging Data Justify a Change in the Standard of Care for Treatment of Na

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 48 Therapy for the VEGF Resistant Patient Biologic Mechsnisms of Resistance, Dr. James Larkin Royal Marsden Hospital, London

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 49

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 50 Existing Clinical Data in VEGF Resistant Disease Jennifer Knox, M.D., Princess Margaret Hospital, Toronto Does the sequen

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 51 VEGF vs mTOR How does the Wyeth 404 result impact Decision making Dr. Thomas Hutson Texas Oncology, Dallas The results o

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 52 Audience dialogue Kaelin why not combination therapy to manage resistance Just because they have not worked to date doesn

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 53 Emerging new agents Once we determine that VEGF is no longer a valid target, what else is there PI3K, Dr. Dan Cho Beth Is

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 54 cMET as a target in RCC cabozaninib, Dr. Toni Choueiri Dana Farber, Boston MET and VEGFR cooperate to promote tumor survi

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 55 How Should You Choose Secondline Therapy for mRCC, Dr. Jorge Garcia Cleveland Clinic What is the biologic or molecular da

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 56 Schoenfeld Lecture ScienceDriven Kidney Cancer Clinical Trials In 1989 Eugene Schonfeld was diagnosed with kidney cancer.

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 57 Award Presentation and Speaker Introduction by Dr. David McDermott Bill Kaelin is the Chief Resident in Kidney Cancer he

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 58 The genes most commonly mutated in ccRCC are VHL, PBRM1, SETD2, BAP1, mTOR. Four of these are on 3p. When you lose 3p, yo

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 59 What we have used so far are different selectivity profiles of kinase inhibitors. Sunitinib is a multitargeted kinase inh

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 60 QA Preclinical models will be important VHL does more than HIF. What about the other branches If you turn off HIF2alpha y

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 61 PD1PDL1 Blockade David F. McDermott, M.D. Beth Israel Deaconess, Boston Immunotherapy is important and we need to work on

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 62 Role of Tumor Microenvironment in RCC James H. Finke, M.D. Cleveland Clinic PDL1 B7H1 expession by RCC and its suppressio

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 63 Immune Checkpoint Inhibitors, Biomarker Development, Rational Combinations, Charles Drake, M.D., Ph. D., Johns Hopkins Wh

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 64 The PISCES and COMPARZ trials showed that Pazopanib was preferred by patients over Sunitinib. However the therapeutic res

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 65 Atkins proposed a new RCC Therapy Algorithm for 2012 RCC Therapy Algorithm 2012 Tumor Markers Treatment choice PDL1 expre

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 66 Editorial Addenda A Closing Note for Consideration by Michael B. Lawing Gap Between Urologist and Survivor Perceptions

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 67 On this question 73 of the doctors that responded strongly agreed they gave their patients clear information whereas 38 o

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 68

Eighth International Kidney Cancer Symposium Chicago 2012 Graff Lawing 69 It should go without saying that the surveys listed above are from a very small group of individuals with no control as t

Share